GW Pharmaceuticals PLC’s (GWPH) “Outperform” Rating Reaffirmed at Cowen and Company
Cowen and Company restated their outperform rating on shares of GW Pharmaceuticals PLC (NASDAQ:GWPH) in a research report sent to investors on Monday morning. The firm currently has a $165.00 target price on the biopharmaceutical company’s stock.
A number of other equities research analysts have also weighed in on GWPH. Maxim Group lowered shares of GW Pharmaceuticals PLC from a buy rating to a hold rating and set a $61.00 target price on the stock. in a report on Tuesday, August 8th. BidaskClub lowered shares of GW Pharmaceuticals PLC from a buy rating to a hold rating in a report on Thursday, August 10th. Leerink Swann restated an outperform rating and issued a $160.00 target price (down previously from $162.00) on shares of GW Pharmaceuticals PLC in a report on Thursday, August 10th. Cantor Fitzgerald set a $208.00 target price on shares of GW Pharmaceuticals PLC and gave the stock a buy rating in a report on Tuesday, August 8th. Finally, Evercore ISI began coverage on shares of GW Pharmaceuticals PLC in a report on Wednesday, August 16th. They issued an outperform rating and a $154.00 target price on the stock. One analyst has rated the stock with a sell rating, three have given a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. GW Pharmaceuticals PLC presently has a consensus rating of Buy and an average price target of $149.83.
GW Pharmaceuticals PLC (GWPH) opened at 114.54 on Monday. GW Pharmaceuticals PLC has a 12-month low of $92.65 and a 12-month high of $137.88. The company’s market cap is $2.90 billion. The firm’s 50-day moving average price is $105.92 and its 200-day moving average price is $108.31.
GW Pharmaceuticals PLC (NASDAQ:GWPH) last posted its earnings results on Monday, August 7th. The biopharmaceutical company reported ($2.07) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.73) by ($0.34). GW Pharmaceuticals PLC had a negative return on equity of 28.80% and a negative net margin of 1,384.41%. The business had revenue of $3.14 million during the quarter, compared to analyst estimates of $2.10 million. During the same quarter in the prior year, the company earned ($0.05) EPS. Equities research analysts forecast that GW Pharmaceuticals PLC will post ($5.94) earnings per share for the current fiscal year.
A number of hedge funds have recently modified their holdings of GWPH. Russell Investments Group Ltd. bought a new stake in GW Pharmaceuticals PLC in the 1st quarter worth about $520,000. Wells Fargo & Company MN grew its position in GW Pharmaceuticals PLC by 10.2% in the 1st quarter. Wells Fargo & Company MN now owns 11,462 shares of the biopharmaceutical company’s stock worth $1,386,000 after purchasing an additional 1,063 shares in the last quarter. Karp Capital Management Corp bought a new stake in GW Pharmaceuticals PLC in the 1st quarter worth about $365,000. Ameriprise Financial Inc. bought a new stake in GW Pharmaceuticals PLC in the 1st quarter worth about $230,000. Finally, Parametric Portfolio Associates LLC grew its position in GW Pharmaceuticals PLC by 21.4% in the 1st quarter. Parametric Portfolio Associates LLC now owns 5,132 shares of the biopharmaceutical company’s stock worth $621,000 after purchasing an additional 903 shares in the last quarter. 75.06% of the stock is owned by institutional investors and hedge funds.
About GW Pharmaceuticals PLC
GW Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing therapeutics from its cannabinoid product platform in a range of disease areas. The Company’s lead cannabinoid product candidate is Epidiolex, which is a liquid formulation of pure plant-derived cannabidiol (CBD).
Receive News & Ratings for GW Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.